In 2018, as part of the next stage in the development of its pulmonology portfolio, Nativa, a pharmaceutical company, will launch the manufacturing of multi-dose powder inhalers for the treatment of bronchopulmonary diseases.
This will include the full-cycle manufacturing ranging from production of substances to packaging of finished dosage forms. The total investments are more than 5 million euros. The company wants to capture more than half of the market, which currently offers only imported products.
The custom-made manufacturing equipment of European brands with unique characteristics have been already delivered to Russia and will be installed at the contract manufacturing site of Nativa LLC in the facilities of Pharmstandart JSC in the city of Kursk.
During the first stage, the company plans to produce more than 450 thousand packages a year, or about 20% of this market segment. After reaching its capacity of about 1.3 million packages a year, the manufacturing operations of Nativa will be able to meet most needs of Russian patients in the medication for the treatment of bronchial asthma.
“The manufacturing of Russian-made multi-dose powder inhalers is an important milestone both for the development of our company and the industry in general. This involves the transfer of technology and strengthens the national security due to the production of medicinal product that has not been previously manufactured in Russia. The establishment of manufacturing area for Nativa LLC at a contract manufacturing site in Kursk opens broad prospects for entering the foreign markets,” said Alexander Malin, the General Director of Nativa.